Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study

Katsiaryna Holl; Andrzej M Nowakowski; Ned Powell; W Glenn McCluggage; Edyta C Pirog; Sabrina Collas De Souza; Wiebren A Tjalma; Mats Rosenlund; Alison Fiander; Maria Castro Sánchez; Vasileia Damaskou; Elmar A Joura; Benny Kirschner; Robert Koiss; John O'Leary; Wim Quint; Olaf Reich; Aureli Torné; Michael Wells; Lukas Rob; Larisa Kolomiets; Anco Molijn; Alevtina Savicheva; Elena Shipitsyna; Dominique Rosillon; David Jenkins

doi:10.1002/ijc.29651

Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study

Katsiaryna Holl, Andrzej M Nowakowski, Ned Powell, W Glenn McCluggage, Edyta C Pirog, Sabrina Collas De Souza, Wiebren A Tjalma, Mats Rosenlund, Alison Fiander, Maria Castro Sánchez, Vasileia Damaskou, Elmar A Joura, Benny Kirschner, Robert Koiss, John O'Leary, Wim Quint, Olaf Reich, Aureli Torné, Michael Wells, Lukas RobLarisa Kolomiets, Anco Molijn, Alevtina Savicheva, Elena Shipitsyna, Dominique Rosillon, David Jenkins

Department of Clinical Medicine

72 Citations (Scopus)

Abstract

Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.

Original language	English
Journal	International Journal of Cancer
Volume	137
Issue number	12
Pages (from-to)	2858-68
Number of pages	11
ISSN	0020-7136
DOIs	https://doi.org/10.1002/ijc.29651
Publication status	Published - 15 Dec 2015

Keywords

Adult
Aged
Carcinoma, Adenosquamous
Cervical Intraepithelial Neoplasia
Cross-Sectional Studies
Europe
Female
Human papillomavirus 16
Humans
Middle Aged
Papillomavirus Infections
Prevalence
Retrospective Studies
Uterine Cervical Neoplasms
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ijc.29651Licence: CC BY-NC-ND

ijc.29651Final published version, 318 KBLicence: CC BY-NC-ND

Cite this

Holl, K., Nowakowski, A. M., Powell, N., McCluggage, W. G., Pirog, E. C., Collas De Souza, S., Tjalma, W. A., Rosenlund, M., Fiander, A., Castro Sánchez, M., Damaskou, V., Joura, E. A., Kirschner, B., Koiss, R., O'Leary, J., Quint, W., Reich, O., Torné, A., Wells, M., ... Jenkins, D. (2015). Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. International Journal of Cancer, 137(12), 2858-68. https://doi.org/10.1002/ijc.29651

Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias : Results from a European multinational epidemiological study. / Holl, Katsiaryna; Nowakowski, Andrzej M; Powell, Ned et al.

In: International Journal of Cancer, Vol. 137, No. 12, 15.12.2015, p. 2858-68.

Research output: Contribution to journal › Journal article › Research › peer-review

Holl, K, Nowakowski, AM, Powell, N, McCluggage, WG, Pirog, EC, Collas De Souza, S, Tjalma, WA, Rosenlund, M, Fiander, A, Castro Sánchez, M, Damaskou, V, Joura, EA, Kirschner, B, Koiss, R, O'Leary, J, Quint, W, Reich, O, Torné, A, Wells, M, Rob, L, Kolomiets, L, Molijn, A, Savicheva, A, Shipitsyna, E, Rosillon, D & Jenkins, D 2015, 'Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study', International Journal of Cancer, vol. 137, no. 12, pp. 2858-68. https://doi.org/10.1002/ijc.29651

@article{95866c055c6a469baa9a26379537c303,

title = "Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study",

abstract = "Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.",

keywords = "Adult, Aged, Carcinoma, Adenosquamous, Cervical Intraepithelial Neoplasia, Cross-Sectional Studies, Europe, Female, Human papillomavirus 16, Humans, Middle Aged, Papillomavirus Infections, Prevalence, Retrospective Studies, Uterine Cervical Neoplasms, Young Adult",

author = "Katsiaryna Holl and Nowakowski, {Andrzej M} and Ned Powell and McCluggage, {W Glenn} and Pirog, {Edyta C} and {Collas De Souza}, Sabrina and Tjalma, {Wiebren A} and Mats Rosenlund and Alison Fiander and {Castro S{\'a}nchez}, Maria and Vasileia Damaskou and Joura, {Elmar A} and Benny Kirschner and Robert Koiss and John O'Leary and Wim Quint and Olaf Reich and Aureli Torn{\'e} and Michael Wells and Lukas Rob and Larisa Kolomiets and Anco Molijn and Alevtina Savicheva and Elena Shipitsyna and Dominique Rosillon and David Jenkins",

note = "{\textcopyright} 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.",

year = "2015",

month = dec,

day = "15",

doi = "10.1002/ijc.29651",

language = "English",

volume = "137",

pages = "2858--68",

journal = "Radiation Oncology Investigations",

issn = "0020-7136",

publisher = "JohnWiley & Sons, Inc.",

number = "12",

}

TY - JOUR

T1 - Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias

T2 - Results from a European multinational epidemiological study

AU - Holl, Katsiaryna

AU - Nowakowski, Andrzej M

AU - Powell, Ned

AU - McCluggage, W Glenn

AU - Pirog, Edyta C

AU - Collas De Souza, Sabrina

AU - Tjalma, Wiebren A

AU - Rosenlund, Mats

AU - Fiander, Alison

AU - Castro Sánchez, Maria

AU - Damaskou, Vasileia

AU - Joura, Elmar A

AU - Kirschner, Benny

AU - Koiss, Robert

AU - O'Leary, John

AU - Quint, Wim

AU - Reich, Olaf

AU - Torné, Aureli

AU - Wells, Michael

AU - Rob, Lukas

AU - Kolomiets, Larisa

AU - Molijn, Anco

AU - Savicheva, Alevtina

AU - Shipitsyna, Elena

AU - Rosillon, Dominique

AU - Jenkins, David

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.

AB - Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.

KW - Adult

KW - Aged

KW - Carcinoma, Adenosquamous

KW - Cervical Intraepithelial Neoplasia

KW - Cross-Sectional Studies

KW - Europe

KW - Female

KW - Human papillomavirus 16

KW - Humans

KW - Middle Aged

KW - Papillomavirus Infections

KW - Prevalence

KW - Retrospective Studies

KW - Uterine Cervical Neoplasms

KW - Young Adult

U2 - 10.1002/ijc.29651

DO - 10.1002/ijc.29651

M3 - Journal article

C2 - 26096203

SN - 0020-7136

VL - 137

SP - 2858

EP - 2868

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

IS - 12

ER -

Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this